---
title: "McDonald's | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 7.078 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264426000.md"
datetime: "2025-11-05T12:06:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264426000.md)
  - [en](https://longbridge.com/en/news/264426000.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264426000.md)
generator: "portal-rs"
---

# McDonald's | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 7.078 B

Revenue: As of FY2025 Q3, the actual value is USD 7.078 B, missing the estimate of USD 7.089 B.

EPS: As of FY2025 Q3, the actual value is USD 3.18, missing the estimate of USD 3.3152.

EBIT: As of FY2025 Q3, the actual value is USD 3.355 B.

### Segment Revenue

-   **Total Revenues**: McDonald’s Corporation reported total revenues of $7,078 million for the quarter ended September 30, 2025, reflecting a 3% increase from $6,873 million in the same period of 2024.
-   **Revenues from Franchised Restaurants**: $4,363 million, up 7% from $4,094 million in the prior year.
-   **Sales by Company-owned and Operated Restaurants**: $2,563 million, a decrease of 3% from $2,656 million in the prior year.
-   **Franchised Revenues**: In the U.S., franchised revenues were $1,906 million, an increase of 3% from the previous year. International Operated Markets saw a 10% increase to $1,962 million, while International Developmental Licensed Markets & Corporate increased by 8% to $496 million.
-   **Company-owned and Operated Sales**: U.S. sales decreased by 4% to $790 million. International Operated Markets increased by 11% to $1,645 million, while International Developmental Licensed Markets & Corporate decreased by 63% to $128 million.

### Operational Metrics

-   **Operating Income**: $3,357 million for the quarter, an increase of 5% from $3,188 million in the prior year.
-   **Net Income**: $2,278 million for the quarter, up 1% from $2,255 million in the prior year. For the nine months, net income increased 3% to $6,399 million.
-   **Operating Margin**: The operating margin for the quarter was 46.5%, up from 45.3% in the previous year.
-   **Operating Costs and Expenses**: Total operating costs and expenses were $3,721 million, a slight increase from $3,685 million in the prior year.
-   **Selling, General & Administrative Expenses**: Increased by 21% for the quarter and 5% for the nine months, primarily due to marketing initiatives and investments in digital and technology.

### Cash Flow

-   **Dividends and Share Repurchases**: During the quarter, the company paid a dividend of $1.77 per share, totaling $1,262 million, and repurchased 1.7 million shares for $503 million.

### Unique Metrics

-   **Systemwide Sales**: Over $36 billion for the quarter, an increase of 8% (6% in constant currency) compared to the prior year.
-   **Sales to Loyalty Members**: Approximately $34 billion for the trailing twelve-month period and over $9 billion for the quarter.
-   **Comparable Sales**: Increased by 3.6% for the quarter and 2.2% for the nine months, driven by positive performance in International Operated Markets and International Developmental Licensed Markets.

### Outlook / Guidance

-   McDonald’s Corporation is focused on delivering sustainable growth through everyday value, menu innovation, and compelling marketing strategies.
-   The company is modernizing its ways of working through restructuring efforts, which incurred pre-tax charges of $39 million for the quarter.
-   McDonald’s expects net restaurant unit expansion to contribute over 2% to 2025 Systemwide sales growth. The operating margin is expected to be in the mid-to-high 40% range, and capital expenditures are projected to be between $3.0 and $3.2 billion, with plans to open approximately 2,200 restaurants globally.

### Related Stocks

- [MCD.US](https://longbridge.com/en/quote/MCD.US.md)

## Related News & Research

- [India extends duty-free cotton imports by two months to ease domestic prices](https://longbridge.com/en/news/303818982.md)
- [Dodla Dairy Limited (NSE:DODLA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year](https://longbridge.com/en/news/303820105.md)
- [Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.](https://longbridge.com/en/news/303820254.md)
- [BIKE Subsidiary Karya Bersinar Indonesia Wins Rp 3.8 Trillion Power Plant Contract From PLN Indonesia Power](https://longbridge.com/en/news/303818847.md)
- [Kite: Affected KITE tokens are frozen after Binance security incident - 31 Oct 2026](https://longbridge.com/en/news/303817980.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**